Greef Roderick De Sells 46,896 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De sold 46,896 shares of the firm’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $23.43, for a total transaction of $1,098,773.28. Following the transaction, the chief executive officer now directly owns 414,958 shares in the company, valued at $9,722,465.94. This represents a 10.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

BioLife Solutions Trading Up 2.1 %

BLFS opened at $27.69 on Friday. The company’s 50 day moving average is $25.99 and its 200-day moving average is $24.29. The company has a market cap of $1.28 billion, a P/E ratio of -26.12 and a beta of 1.92. BioLife Solutions, Inc. has a 1-year low of $14.50 and a 1-year high of $28.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently modified their holdings of BLFS. Principal Financial Group Inc. lifted its stake in shares of BioLife Solutions by 4.7% in the 3rd quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock valued at $4,776,000 after acquiring an additional 8,580 shares during the last quarter. Barclays PLC raised its position in BioLife Solutions by 20.1% in the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after purchasing an additional 10,803 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares in the last quarter. State Street Corp boosted its stake in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Northland Securities lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday. KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Craig Hallum increased their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Benchmark restated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, HC Wainwright reduced their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.